CORBEVAX receives DCGI approval for Emergency Use Authorization (EUA) for 12-18 years age group

What is the News?

Drugs Controller General of India(DGCI) has given emergency use authorisation to Corbevax vaccine for use in children between 12 and 18 years of age.

What is Corbevax Vaccine?

Corbevax is India’s first indigenously developed Receptor Binding Domain (RBD) protein subunit vaccine.

Manufactured by: Hyderabad-based Biological E.

Click Here to read more about Corbevax

Is this the first vaccine approved for use in Children?

No, Corbevax is the third vaccine approved by the DCGI for children’s use after Covaxin and Zydus Cadila’s ZyCoV-D. 

But currently, only Covaxin is used in the inoculation drive for children in the 15-18 age group. 

Source: This post is based on the article “CORBEVAX receives DCGI approval for Emergency Use Authorization (EUA) for 12-18 years age group” published in PIB on 25th February 2022